Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12605310 | Non-aqueous dispersion, preparation method therefor, and cosmetic composition comprising same | 🖼🧊📄§ | 2026-04-21 | 2039-10-08 | 0 | 31 |
| 12605308 | Topical skin care formulations comprising plant extracts | 🖼🧊📄§ | 2026-04-21 | 2043-10-18 | 0 | 31 |
| 12605309 | Pressed powder product and method for preparing the same | 🖼🧊📄§ | 2026-04-21 | 2043-05-25 | 0 | 31 |
| 12605316 | Alkenone-based formulations for topical applications | 🖼🧊📄§ | 2026-04-21 | 2043-11-02 | 0 | 31 |
| 12605323 | Composition for inhibiting hair graying, and use thereof | 🖼🧊📄§ | 2026-04-21 | 2040-05-28 | 0 | 31 |
| 12605327 | Hair cosmetic compositions | 🖼🧊📄§ | 2026-04-21 | 2041-02-28 | 0 | 31 |
| 12605336 | Fusogenic liposome-coated porous silicon nanoparticles | 🖼🧊📄§ | 2026-04-21 | 2042-07-22 | 0 | 31 |
| 12605333 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | 🖼🧊📄§ | 2026-04-21 | 2042-04-21 | 0 | 31 |
| 12605341 | Dry powder composition for peroral administration | 🖼🧊📄§ | 2026-04-21 | 2043-10-23 | 0 | 31 |
| 12605340 | Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide | 🖼🧊📄§ | 2026-04-21 | 2041-05-15 | 0 | 31 |
| 12605346 | Composition containing curcumin compound, and method for producing same | 🖼🧊📄§ | 2026-04-21 | 2041-01-25 | 0 | 31 |
| 12605353 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | 🖼🧊📄§ | 2026-04-21 | 2040-11-15 | 0 | 31 |
| 12605354 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | 🖼🧊📄§ | 2026-04-21 | 2041-02-19 | 0 | 31 |
| 12605356 | Methods of treating pancreatic cancer | 🖼🧊📄§ | 2026-04-21 | 2043-10-26 | 0 | 31 |
| 12605352 | Compositions and methods for inhibiting blood cancer cell growth | 🖼🧊📄§ | 2026-04-21 | 2040-04-20 | 0 | 31 |
| 12605361 | Carboxylated psilocybin derivatives and methods of using | 🖼🧊📄§ | 2026-04-21 | 2043-07-28 | 0 | 31 |
| 12605362 | Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function | 🖼🧊📄§ | 2026-04-21 | 2040-12-21 | 0 | 31 |
| 12605360 | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix | 🖼🧊📄§ | 2026-04-21 | 2041-09-22 | 0 | 31 |
| 12605380 | Methods of improving lung function | 🖼🧊📄§ | 2026-04-21 | 2045-09-12 | 0 | 31 |
| 12605377 | Methods of treating fibrosis | 🖼🧊📄§ | 2026-04-21 | 2043-02-28 | 0 | 31 |
| 12605375 | Use of CSF-1R kinase inhibitor | 🖼🧊📄§ | 2026-04-21 | 2041-02-26 | 0 | 31 |
| 12605376 | Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase | 🖼🧊📄§ | 2026-04-21 | 2041-04-01 | 0 | 31 |
| 12605392 | Cannabinoid composition and method of treating diabetic and chemotherapy induced neuropathic pain | 🖼🧊📄§ | 2026-04-21 | 2042-06-20 | 0 | 31 |
| 12605390 | Treatment of cancer and inhibition of metastasis | 🖼🧊📄§ | 2026-04-21 | 2041-10-27 | 0 | 31 |
| 12605394 | Compositions containing cannabinoid nanoparticles | 🖼🧊📄§ | 2026-04-21 | 2044-07-25 | 0 | 31 |
| 12605417 | Compositions and methods for ameliorating symptoms associated with inflammatory skin disorders | 🖼🧊📄§ | 2026-04-21 | 2044-09-27 | 0 | 31 |
| 12605401 | Polymers, compositions and methods for treating hyperuricemia | 🖼🧊📄§ | 2026-04-21 | 2042-05-18 | 0 | 31 |
| 12605404 | Synthetic cellular membrane chemical ionophore delivery system comprising hexa-aqua ligand compositions | 🖼🧊📄§ | 2026-04-21 | 2041-07-30 | 0 | 31 |
| 12605403 | Compositions and methods for treating transient biofilms | 🖼🧊📄§ | 2026-04-21 | 2042-09-26 | 0 | 31 |
| 12605410 | Mitochondria-enriched genetically engineered cells and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2041-03-30 | 0 | 31 |
| 12605407 | Methods to induce terminal differentiation in stem cells by interfering with DNA replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof | 🖼🧊📄§ | 2026-04-21 | 2040-10-27 | 0 | 31 |
| 12605428 | Kinase NEK10 and its use in treating and diagnosing bronchiectasis and other respiratory disorders | 🖼🧊📄§ | 2026-04-21 | 2041-01-19 | 0 | 31 |
| 12605421 | Senescence inhibitor | 🖼🧊📄§ | 2026-04-21 | 2045-03-18 | 0 | 31 |
| 12605420 | Use of plant composition, traditional Chinese medicine composition in preparing medicine for treating COVID-19 | 🖼🧊📄§ | 2026-04-21 | 2042-10-19 | 0 | 31 |
| 12605419 | Flavonoid extract of Cyclocarya paliurus leaves and antibacterial drugs and/or antibacterial agents containing thereof | 🖼🧊📄§ | 2026-04-21 | 2040-08-20 | 0 | 31 |
| 12605425 | TNF muteins and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2040-06-26 | 0 | 31 |
| 12605423 | Peptide inhibitors targeting methyltransfer mechanism of SARS-CoV-2 | 🖼🧊📄§ | 2026-04-21 | 2041-09-08 | 0 | 31 |
| 12605424 | Treatment and prevention of pulmonary injury | 🖼🧊📄§ | 2026-04-21 | 2040-09-04 | 0 | 31 |
| 12605431 | Composition for treating or preventing myopathy, obesity or diabetes | 🖼🧊📄§ | 2026-04-21 | 2041-12-14 | 0 | 31 |
| 12605458 | Antibody-drug conjugate having acidic self-stabilization junction | 🖼🧊📄§ | 2026-04-21 | 2038-06-15 | 0 | 31 |
| 12605413 | Engineered probiotics for treatment and immunity against viruses | 🖼🧊📄§ | 2026-04-21 | 2041-04-19 | 0 | 31 |
| 12605416 | Compositions and methods for the treatment of skin diseases and conditions including eczema | 🖼🧊📄§ | 2026-04-21 | 2044-12-27 | 0 | 31 |
| 12606572 | Substituted heterocycles and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2045-10-07 | 0 | 31 |
| 12605344 | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | 🖼🧊📄§ | 2026-04-21 | 2042-12-16 | 0 | 31 |
| 12605363 | Oxymetazoline compositions | 🖼🧊📄§ | 2026-04-21 | 2042-12-23 | 0 | 31 |
| 12604903 | Antimicrobial NCR peptides | 🖼🧊📄§ | 2026-04-21 | 2040-01-07 | 0 | 31 |
| 12606614 | Human FcRn-binding modified antibodies and methods of use | 🖼🧊📄§ | 2026-04-21 | 2041-07-12 | 0 | 31 |
| 12605396 | Methods of treating mastitis with an orthosomycin antimicrobial compound | 🖼🧊📄§ | 2026-04-21 | 2041-12-23 | 0 | 31 |
| 12605368 | Suppression of neuroinflammation and composition and method therefor | 🖼🧊📄§ | 2026-04-21 | 2041-03-31 | 0 | 31 |
| 12605370 | Agents and compositions for the treatment of glioblastoma | 🖼🧊📄§ | 2026-04-21 | 2041-03-12 | 0 | 31 |